GlassScriptPhysician profile
Milton G Mutchnick
NPI 1407894579
$106,052.89
in general payments reported to CMS, 2019-2025
20 companies · $11K in 2025
The $11K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $16K · 2021: $20K · 2022: $13K · 2023: $1,342 · 2024: $330 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,519 · Food and Beverage: $2,657 · Travel and Lodging: $45.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,519.00 |
| Food and Beverage | $2,656.88 |
| Travel and Lodging | $45.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $56,936.61 | 2019-2025 | Livdelzi, Epclusa |
| Intercept Pharmaceuticals, INC. | $22,547.37 | 2019-2023 | Ocaliva |
| Abbvie INC. | $15,081.65 | 2019-2025 | |
| Madrigal Pharmaceuticals | $10,191.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $673.08 | 2020-2025 | Xifaxan |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.70 | 2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $111.32 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $95.07 | 2022-2023 | Ibsrela |
| Glaxosmithkline, LLC. | $57.09 | 2025 | |
| Qol Medical, LLC | $52.46 | 2021 | |
| Janssen Biotech, INC. | $43.30 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $38.99 | 2021-2022 | |
| Celgene Corporation | $33.82 | 2022 | |
| Smith+Nephew, INC. | $19.74 | 2025 | Pico 7 |
| Alnylam Pharmaceuticals INC. | $18.79 | 2023 | Givlaari |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.44 | 2025 | Wegovy |
| Genzyme Corporation | $15.51 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Mutchnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.